Evidence map›Paper›PMID 26890002›Full record

ArticlePloS one2016

Role of UBIAD1 in Intracellular Cholesterol Metabolism and Vascular Cell Calcification.

Sha Liu, Wang Guo, Xue Han, Wendi Dai, Zongli Diao, Wenhu Liu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Clinical diversity in patients with Schnyder corneal dystrophy-a novel and known UBIAD1 pathogenic variants.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sha LiuDepartment of Nephrology, Beijing Friendship Hospital, Faculty of Nephrology, Capital Medical University, Xicheng District, Beijing, China.
Wang GuoDepartment of Nephrology, Beijing Friendship Hospital, Faculty of Nephrology, Capital Medical University, Xicheng District, Beijing, China.
Xue HanDepartment of Nephrology, Beijing Friendship Hospital, Faculty of Nephrology, Capital Medical University, Xicheng District, Beijing, China.
Wendi DaiDepartment of Nephrology, Beijing Friendship Hospital, Faculty of Nephrology, Capital Medical University, Xicheng District, Beijing, China.
Zongli DiaoDepartment of Nephrology, Beijing Friendship Hospital, Faculty of Nephrology, Capital Medical University, Xicheng District, Beijing, China.
Wenhu LiuDepartment of Nephrology, Beijing Friendship Hospital, Faculty of Nephrology, Capital Medical University, Xicheng District, Beijing, China.
Capital Medical University · CNBeijing Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular calcification is an important risk factor associated with mortality among patients with chronic kidney disease. Intracellular cholesterol metabolism is involved in the process of vascular cell calcification. In this study, we investigated the role of UbiA prenyltransferase domain containing 1 (UBIAD1) in intracellular cholesterol metabolism and vascular cell calcification, and identified its subcellular location. Primary human umbilical vein smooth muscle cells (HUVSMCs) were incubated with either growth medium (1.4 mmol/L Pi) or calcification medium (CM) (3.0 mmol/L Pi). Under treatment with CM, HUVSMCs were further incubated with exogenous cholesterol, or menaquinone-4, a product of UBIAD1. The plasmid and small interfering RNA were transfected in HUVSMCs to alter the expression of UBIAD1. Matrix calcium quantitation, alkaline phosphatase activity, intracellular cholesterol level and menaquinone-4 level were measured. The expression of several genes involved in cholesterol metabolism were analyzed. Using an anti-UBIAD1 antibody, an endoplasmic reticulum marker and a Golgi marker, the subcellular location of UBIAD1 in HUVSMCs was analyzed. CM increased matrix calcium, alkaline phosphatase activity and intracellular cholesterol level, and reduced UBIAD1 expression and menaquinone-4 level. Addition of cholesterol contributed to increased matrix calcification and alkaline phosphatase activity in a dose-dependent manner. Elevated expression of UBIAD1 or menaquinone-4 in HUVSMCs treated with CM significantly reduced intracellular cholesterol level, matrix calcification and alkaline phosphatase activity, but increased menaquinone-4 level. Elevated expression of UBIAD1 or menaquinone-4 reduced the gene expression of sterol regulatory element-binding protein-2, and increased gene expression of ATP binding cassette transporters A1, which are in charge of cholesterol synthesis and efflux. UBIAD1 co-localized with the endoplasmic reticulum marker and the Golgi marker in HUVSMCs. In conclusion, high intracellular cholesterol content contributes to phosphate-induced vascular cell differentiation and calcification. UBIAD1 or menaquinone-4 could decrease vascular cell differentiation and calcification, probably via its potent role of inversely modulating cellular cholesterol.

Indexed as

Alkaline PhosphataseCell DifferentiationCell Membrane PermeabilityCholesterolCulture MediaDimethylallyltranstransferaseEndoplasmic ReticulumExtracellular MatrixGene Expression RegulationGolgi ApparatusHumansIntracellular SpaceMyocytes, Smooth MuscleOsteoblastsPhosphorusUmbilical VeinsAlkaline PhosphataseCholesterolCulture MediaDimethylallyltranstransferasemenatetrenonePhosphorusUBIAD1 protein, humanVitamin K 2

Identifiers

PMID26890002
PMCPMC4758632
OpenAlexW2287069564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.